Organon & Co.

Valuation Analysis

About the Company

Organon & Co. en bref

Organon & Co. (OGN) is currently trading at 11,71 € with a market capitalization of 3,1 Md €. The trailing P/E ratio stands at 14.44x, with a forward P/E of 3.67x. The 52-week range spans from 4,96 € to 11,76 €; the current price is 0.4% below the yearly high. Year-over-year revenue growth stands at -3.5%. The net profit margin stands at 3.99%.

💰 Dividende

Organon & Co. pays an annual dividend of 0,07 € per share, representing a yield of 0.6%. The payout ratio stands at 8.6%.

📊 Avis des analystes

4 analystes évaluent Organon & Co. (OGN) au consensus : None. L'objectif de cours moyen est de 9,81 €, soit un potentiel de -16.2% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 6,97 € à 12,20 €.

Organon & Co. : la thèse d'investissement en détail

Organon & Co. (OGN) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 66.7% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 53.84% gross margin and 18.7% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Return on equity of 34.05% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

Le scénario baissier

Revenue is contracting at -3.5% year-over-year — until that trend reverses, valuation is exposed to further downgrades. With a net margin of just 3.99%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. The debt-to-equity ratio of 948.95% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valorisation en contexte

The EV/EBITDA multiple of 6.88x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 3.67x is meaningfully below the trailing 14.44x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 99.2% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to above-average price swings, elevated short interest (7.82%), higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Organon & Co.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.